ABSTRACT
To E PITOPES FOR thyroid-stimulating autoantibodies (TSHRAbs) that increase CAMP levels have been suggested to reside on the N-terminal portion of the TSH receptor (TSHR) extracellular domain (l-3). Thus, mutation and/or substitution of threonine 40 or residues 30-33,34-37, 42-45,52-56, or 58-61 of the rat TSHR' result in the loss of stimulating TSHRAb activity by Graves' IgGs (l-5). In contrast, their mutation or substitution results in a receptor that retains a near-normal TSH-increased CAMP response and retains blocking TSHRAb activity in IgGs from hypothyroid patients with idiopathic myxedema. Studies using chimeras of the human TSHR (hTSHR) and the LH-CG receptor (LH-CGR) are consistent with these observations (l-3,6-9). Thus, if residues 8 -165 or 90 -165 of the TSHR are substituted with equivalent regions of the LH-CGR, chimeras Mc1+2 and Mc2, respectively (Fig. l) , stimulating TSHRAb activity is lost in Graves' IgGs, whereas TSH and blocking TSHRAb activities are retained compared to wild-type receptor.
The clinical relevance or applicability of these data is not clear. Thus, these studies evaluated relatively small numbers of patients (12 or fewer) and used transient transfection techniques. Also, evidence from both types of studies suggests that stimulating TSHRAbs are a heterogeneous population when evaluated using different mutants or chimeras. Finally, although the hTSHR chimera studies were consistent with the mutation or substitution studies using the rat TSHR and although epitopes identified in the rat TSHR studies involve residues identical to those in the hTSHR, studies using the rat TSHR are still questioned by some. To address these concerns, we created stably transfected Chinese hamster ovary (CHO) cells containing the hTSHR, the Mel +2 hTSHR-LH/ CGR chimeric receptor, or the Mc2 chimera; developed optimal assays using these cells; and evaluated the activities of IgG from 66 patients with untreated Graves' disease.
Materials and Methods

Materials
The CAMP RIA kits were obtained from Incstar (Minnesota, 
Cell viability assays
Cell viability was tested by a dye exclusion procedure (11) after incubation for l-3 h in the above-mentioned incubation media. After aspirating the incubation medium, cells were washed with 1 mL Ca2+-and Mg2+-free HBSS, trypsinized with 0.1 mL 0.05% trypsin-ethylenediamine tetraacetate for 5 min before the addition of 0.9 mL serum-containing medium, and stained with 0.4% trypan blue. The percentage of stained to total cells was determined with a hemocytometer within l-2 min of staining.
To exclude bias resulting from the trypsinization procedure, cells in situ were stained after a 2-h incubation in each medium and were observed under the microscope; no apparent difference was observed.
Measurements
of thyroid hormones and autoantibodies Serum free T, and total T, concentrations were measured using commercial kits (Abbott, North Chicago, IL); the normal ranges were 0. (Fig. l) , in which residues 8-165 or 90-165, respectively, of the hTSHR were substituted with equivalent portions of the LH/CGR. This system was tested because preliminary evidence had suggested that this region of the TSHR included a significant portion of the stimulating TSHR epitopes in either a linear or conformational array, yet could still measure epitope heterogeneity (l-9). cell viability. Thus, the percent cells stained with trypan blue after incubation for 1, 2, or 3 h in hypotonic buffer was significantly higher (6-9% vs. 2% in isotonic medium; P < 0.05). This is not the case in FRTL-5 cells (data not shown). Additionally, there is no difference in basal values between isotonic (medium A) and hypotonic assay conditions (medium B) using FRTL-5 cells (2.3 '-c 0.5 pmol/well in both cases); this phenomenon appears, therefore, to be an effect on the TSHR in transfected cells and does not reflect a buffer-IgG interaction.
Current stimulating TSHRAb assays in most cell systems, for example the rat FRTL-5 cell, use a hypotonic buffer with no NaCl to optimize the assay (9,10,13). This assay has the advantage that CAMP levels are readily measured extracellularly, simplifying the RIA. In this medium, bTSH produced a concentration-dependent increase in extracellular CAMP levels in the CHO-25 cells stably transfected with the hTSHR (Fig. 2) . However, the maximal increase was only 8-fold above maximal, which was considered inadequate.
The isotonic assay buffer with no NaCl was also best for measuring Graves' IgG activity (Fig. 3B) . Thus, by comparison to the hypotonic, no NaCl condition, basal CAMP values were significantly lower, as was the case for TSH (data not shown). This results in a higher stimulation index (Fig. 3B ) when measured over a lo-fold range of IgG concentrations. As previously reported in other cell systems (10, 13), the presence of high salts in the assay medium is particularly devastating for measurement of Graves' IgG activity (Fig.  3B ). Transient transfection studies using the rat TSHR sugUsing the optimized assay condition, CHO-25-hTSHRgested that CHO and COS-7 cells did not survive in hypotransfected cells exhibited a higher maximal response to tonic medium as did FRTL-5 cells (4, 5, 9). We, therefore, bTSH ( Fig. 4A ) or a pooled Graves' IgG preparation ( Fig. 4B ) modified the incubation to include 222 mmol/L sucrose, than did FRTL5 thyroid cells. Moreover, they exhibited a creating an isotonic assay buffer with no NaCl, in which the higher sensitivity to bTSH and the pooled Graves' IgG when CAMP was still readily measured extracellularly (4, 5, 9).
evaluated as a function of TSH or IgG concentration (Fig. 4 , Under these conditions, basal levels decreased, the maximal A and B, respectively). The optimal incubation time for TSH-TSH response increased, and the sensitivity of detection inor IgG-induced increases was 2 h in the CHO-hTSHR system creased in the CHO-hTSHR system (Fig. 2) . Thus, evaluated (data not shown). The intra-and interassay variations in as a percentage of basal values using a wide range of bTSH stimulating TSHRAb activity measurements was good (3.9-concentrations and comparing different conditions (Fig. 3A) , 9.0% and 12.7-16.6%, respectively) despite differences in the the isotonic assay buffer with sucrose but no NaCl (medium mean stimulating TSHRAb activity from 119-3895% above A) yielded significantly higher stimulation indexes, particbasal. The detection frequency and specificity of the assay ularly at lower concentrations of TSH (P < 0.05 when evalwith CHO-25-hTSHR-transfected cells were also excellent for uated against either medium by one-way ANOVA). One this type of bioassay (Fig. 5) . Thus, stimulating TSHRAb explanation for the difference between isotonic (medium A) activity was detected in 90% of patients with untreated and hypotonic assay conditions (medium B) was decreased Graves' disease when patients initially presented ( nontoxic goiter, 1 of 15 patients with primary myxedema, and 2 of 33 control patients with no thyroid disease (Fig. 5) . Again, these data are in reasonable agreement with those from other studies (10, 14-19).
The CHO hTSHR/chimera assay system to measure Graves' IgG epitopes, heterogeneity, and clinical efficacy of antithyroid drug therapy
Using the optimized assay conditions, we first compared the activity of bTSH and the pooled Graves' IgG in CHO-25 cells containing wild-type hTSHR and in CHO cells stably transfected with the Mc1+2 or Mc2 hTSHR-LH/CGR chimeras (Fig. 6) . The CAMP response to TSH was similar in wild-type and MQ-transfected cells (Fig. 6A) . TSH was also effective in the Mcl+2-transfected cells, with a slight in- crease in response sensitivity at lower TSH concentrations, albeit a lower maximal response (Fig. 6A) . The pooled Graves' IgG exhibited, in contrast, no activity in the Mc2-or Mel +2-transfected cells compared to the CHO-25-wild-type TSHR transfectant, even when tested over a wide range of IgG concentrations (Fig. 6B ). These data show that the Graves' IgG activation of the TSHR requires epitopes on the N-terminus of the hTSHR, affirming studies with the rat TSHR (l-5). Moreover, they establish that residues 90-165 are important in addition to residues between 30-70 detected in the substitution and mutagenesis studies of the rat TSHR (l-5).
We next compared the activities of IgG from 66 untreated Graves' patients in the CHO-hTSHR/chimera assay system ( Fig. 7 and Table 1 ). Of 66 IgGs tested, 63 (95%) were positive in the CHO-25-wild-type TSHR transfectants (Fig. 7 , column I). Forty-five of the 66 patients (68%) had antibodies whose activity completely depended on the N-terminal region of the extracellular domain. Thus, six of the 66 were also positive in the Mel +2-chimeric TSHR-LH/CGR-transfected cells (Fig. 7 , column 2, and Table l), 12 of 66 were positive in the Mc2-chimeric TSHR-LH/CGR-transfected cells (Fig. 7 , column 3, and Table l), and 3 were positive in both (Fig. 7 , coltlmrzs 2 and 3, and Table 1 ). Of the patients whose IgG exhibited activity in the chimeras, all but 4 had a major decrease in activity in the chimeras compared to their values in assays with wild-type hTSHR (Table 1) . Thus, in 94% of patients (62 of 661, the N-terminus of the hTSHR was a required epitope for either all or the vast majority of stimulating TSHRAbs present in their IgG (Fig. 7 and Table 11 , consistent with data obtained in studies of the rat TSHR (l-5) and in initial hTSHR chimera studies using transient transfection procedures (l-3, 6-9).
Unexpectedly, the chimera data raised an issue of even greater potential interest when epitope heterogeneity was considered with respect to their clinical responses to anti- thyroid drug therapy. Thus, approximately 30% of patients have stimulating TSHRAbs whose activity depends on sites other than the N-terminal locus despite the fact the activity of the majority of their stimulating TSHRAbs depend on sites within the N-terminal region of the extracellular domain (Table 2 ). When patients were divided into two groups [group A, containing individuals whose IgG exhibited residual activity in one or both chimeras (Table 2) , and group B, containing individuals whose stimulating TSHRAb activity depended only on epitopes in the N-terminal portion of the extracellular domain (Table 2 )], a difference in clinical response to antithyroid drug therapy was evident (Table 3) . Thus, in patients from group A who received methimazole or propylthiouracil therapy only, i.e. excluding two patients who received radioiodine therapy, 94% became euthyroid within 3 months, whereas this was true of only 70% of group B patients (Table 3A) . Euthyroidism was judged both clinically and by the return of T, levels to normal. Further, there was a decrease in the duration of therapy necessary to achieve a euthyroid state in the responsive patients in group A (Table 3B) . Thus, 94% of group A patients who responded required only 2 months of treatment, whereas only 73% of group B patients responded within 2 months. The existence of epitope heterogeneity in a patient, i.e. of stimulating TSHRAbs with epitopes other than on the N-terminal region of the extracellular domain, is, therefore, unexpectedly associated with an apparently improved clinical response to antithyroid drug therapy.
Other differences existed in the two groups. Thus, mean values for initial measurements of TBII activity tended to be higher in group A than in group B patients (Fig. 8A) , although the difference exhibited only borderline significance. However, TBII values declined significantly in the group A patients treated with antithyroid drugs and followed over an g-month period (P < 0.05), whereas this was not the case in group B patients (Fig. 8, A and B) . Patients in group A also had higher mean values for stimulating TSHRAb activity whether measured in CHO-25 cells containing transfected hTSHR or rat FRTL-5 thyroid cells (Table 4 ). There was no significant difference in age, family history, mean goiter size, or initial thyroid function parameters in the two groups (Table 4 ). There is a tendency for a greater female to male ratio in group A and, possibly, a higher frequency of ophthalmopathy; however, no statistically significant difference in these parameters could be calculated when comparing the groups at this time. rat FRTL-5 cell assays By comparison to rat FRTL5 cell assays reported in multiple laboratories (13-l@, the detection of positive values for stimulating TSHRAb activity in patients with untreated Graves' disease when patients initially presented was comparable in the CHO-25-transfected hTSHR assay system, i.e. about 90 2 5%. Using the mean value for stimulating TSHRAb activity measured in the pool of 30 Graves' IgGs as an arbitrary dividing point for assays in the CHO-25-hTSHR and FRTL-5 systems of IgGs simultaneously evaluated and positive in both (Fig. 9) , 9 patients had high values in both assays, and 30 had low values in both assays. Seven patients had high values in the CHO-25-hTSHR assay, but low values in FRTL-5 cells; in contrast, 11 had low values in CHO-25 hTSHR assays and high values in FRTL5 cell assays ( Fig. 9 and Table 5 ). This distribution is similar to that reported in early studies comparing human primary and rat FRTL5 cell assays (20). Thus, approximately 70% of the patient IgGs exhibit similarly high or low values in both assays, and lo-20% have disparate values, high in one assay or low in the other.
Comparison of the assay values in the two systems yielded, nevertheless, surprising findings (Tables 5 and 6 ). First, patients who had IgGs with high values in CHO-25 cells with the hTSHR tended to have higher serum T, and T, values (Table 5 , bold values). This observation was supported when the level of stimulating TSHRAb activity in the CHO-25 and FRTL5 cells was compared with serum T, and T, values. Correlation coefficients were significantly better with CHO-25-hTSHR than with FRTL-5 cell values (Table 6 , bold and underlined values); P values analyzed by ANOVA were less than 0.05 and 0.01, respectively, for T, and T,. In contrast, patients who had IgGs with high values in FRTL-5 cells tended to have larger goiters (Table 5 , bold and italicized values; P < 0.05, by ANOVA), although no significant difference in correlation coefficient existed when all stimulating TSHRAb values measured in each cell system were considered (Table 6 , bottom YOW). The difference between function and goiter size with respect to stimulating TSHRAb measurements in the two systems was, nevertheless, particularly evident in the free T,/goiter ratio in patients with high CHO-25 and low FRTL5 cell assaT values (Table 5 , last row, bold value; P < 0.01, by ANOVA). 9 "Tc pertechnetate uptake was also higher in patients who had higher stimulating TSHRAb activities in FRTL-5 cells (Table 5 , bold values; Table  6 , bold v&es); correlation coefficient analysis (Table 6 ) reveals a significant P value (P < 0.01, by ANOVA) when 20-min Tc uptake was compared with all FRTL-5 and CHO-25 cell stimulating TSHRAb values.
In sum, stimulating TSHRAb activities measured in the FRTL5 system tended to correlate with goiter size and Tc uptake, whereas stimulating activities measured in the CHO-25-hTSHR/chimera system correlated better with T, and T4 levels. This supports the suggestion that stimulating TSHRAb activity measured in the two assays may not represent identical populations of stimulating antibodies.
When the TBII values of an IgG were compared with its stimulating TSHRAb activity in the CHO-25 hTSHR system, there was no simple quantitative correlation (data not presented). This is consistent with studies suggesting that the two antibody populations, TBIIs and stimulating TSHRAbs, are not identical in studies of monoclonal TSHR antibodies (21,22), nor are their activities identically preserved in CHO cells transfected with the Mel +2 or Mc2 chimeras (Tahara, K., and L. D. Kohn, manuscript in preparation). Nevertheless, there were higher TBII values in patients with high stimulating TSHRAb activity in both the FRTL5 and CHO-25-hTSHR cell assays than in patients whose IgGs had low values in both assays or high values in one but low values in the other (Table 5) .
Discussion
The present report describes a stably transfected hTSHR assay system in CHO cells involving wild-type TSHR and two TSHR-LH/CGR chimeras, Mc1+2 and Mc2, with substitutions of different regions of the N-terminal portion of the hTSHR, residues 8-165 and 90-165, respectively. In evaluating 87 patients with untreated Graves' disease, the wildtype hTSHR-transfected CHO-25 cells exhibit an ability to detect stimulating TSHRAb activity in IgGs similar to the best results in FRTL5 cells (13-18) and in a CHO hTSHR system previously described (19). There is, nevertheless, an important technical caveat worth noting. The CHO hTSHR assay requires an isotonic buffer system with no salts to optimize results. This buffer suppresses basal CAMP values in the TSHR-transfected cells, and it is suppression of the basal activity and expression of data as a percentage of basal with normal IgG that are critical for the success of the system. High basal CAMP values in TSHR-transfected cells were evident in studies of rat TSHR in COS-7 cells (4,5). Mutations ). This appears to be unique to TSHR compared to LH/CGR-transfected cells (9). The basis for this is unclear; nevertheless, the influence of isotonicity on the assay system is obvious. This phenomenon is not a buffer effect on IgG, because there is no difference in basal values when the two conditions are compared in FRTL5 cell assays. Effects of salts on TSHR-G, coupling have been reported (26). The use of a CHO or other type of cell transfected with wild-type hTSHR has advantages and disadvantages as an assay system for detecting TSHRAbs, as will be discussed below. The ability to combine measurements of stimulating TSHRAb activity in CHO cells transfected with wild-type hTSHR with measurements in CHO cells transfected with a hTSHR that has substitutions of different regions of the extracellular domain already has meaning beyond this; this will, therefore, be considered first.
Transient transfection studies of rat TSHR mutants as well as initial studies using the TSHR-LH/CGR chimeras used herein suggested that epitopes for stimulating TSHR autoantibodies are on the N-terminus of the extracellular domain of the TSHR (l-9). The use of the stably transfected CHO-25-hTSHR/chimera system described herein has placed this observation in clinical perspective and established its clinical relevance. First, it is clear that the majority of stimulating TSHRAbs in patients with Graves' disease require the Nterminal region of the extracellular domain of the hTSHR for activity, exactly as predicted in the rat TSHR studies (l-5). Stimulating TSHRAb activity is lost completely in 65% of patients when Mc1+2 or Mc2 chimeras are tested; in an additional 30% of patients, the major portion of the stimulating TSHRAb activity is lost.
Second, it is evident that many or most of the stimulating TSHRAbs require residues 90-165 for activity. Previous studies (l-5) involving Third, the use of stably transfected chimeras allowed the ready detection of stimulating TSHRAbs involving epitopes other than the N-terminal portion of the TSHR extracellular domain, thereby readily defining epitope heterogeneity. The basis for this is unclear. These can be stimulating TSHRAbs that are able to interact with other regions of the TSHR, yet can use the N-terminal region of the LH/CGR to transmit the signal, as in the case of TSH itself. This is suggested in separate studies of the Mel +2 chimera and its comparative activities with TSH, LH, or hCG (9). It is also suggested in studies showing that peptides to the C-terminal immunogenic TSHR domain adsorb stimulating TSHRAb activity because these antibodies also bind to the N-terminus of the TSHR (27, 28), i.e. adsorption or inhibition activity by the former peptides are specifically inhibited by the latter.
Fourth, use of the stably transfected chimeras has allowed us to see for the first time the potential clinical relevance of stimulating TSHRAb heterogeneity. Thus, we show that patients with a heterogeneous population of stimulating TSHRAbs involving receptor determinants other than the N-terminus have a better clinical response to antithyroid drug therapy. They achieve euthyroidism faster and more often than do patients with no such heterogeneity despite the fact their stimulating TSHRAb activities and TBII levels tend to be higher when first seen. The fact that 95% of these patients remit on drug therapy within 3 months and that their TBII levels fall significantly make the identification and
follow-up of this group important. Thus, the data predict a different clinical course hitherto unrevealed by assays in any other system. Certainly the real issue in terms of clinical relevance will be whether the difference in the antithyroid drug response is associated with a difference in the remission rate. If, with long term follow-up, these patients have a lower recurrence rate, identification of the group will have a significant impact on the morbidity and cost of treatment. It is not an insignificant group, i.e. group A appears to represent approximately 30% of the Graves' population.
The basis for the difference in response to antithyroid drugs is not clear. One possibility is that the patients with epitopes other than in the N-terminus may be at an earlier stage of disease, wherein the epitope walking process involving the immunogenic domain predicted in studies of the rat TSHR is incomplete (29). Alternatively or in addition, blocking autoantibodies to the C-terminus of the TSHR may be present in these patients (l-7,30,31), accounting for the higher TBII values and contributing to a more rapid return to euthyroidism.
This possibility would not, however, be consistent with the existence of the higher mean stimulating TSHRAb activities in the group A patients. The present experiments are aimed at resolving these issues. Studies are in progress to detect and follow blocking TSHRAbs in this group of patients using the Mc1+2 or Mc2 chimeras and other mutants. The incidence and level of antibodies to the immunogenic domain of the TSHR (29, 32, 33) will also be evaluated, as will the ability of peptides from the immunogenic domain to adsorb stimulating TSHRAb activity in this group compared to group B patients. Nevertheless, use of the assay system described herein to evaluate Graves' populations in other countries and laboratories is important to confirm the present data, as they preliminarily open a new clinical approach to treating and understanding the disease process.
Returning to the issue of CHO cells stably transfected with wild-type hTSHR as an assay system to measure stimulating TSHRAbs, there are several additional points to note. Certainly in a highly selected, sensitive transfectant, the frequency of positives is as good as that in the FRTL-5 system (13-l@, and the maxima above basal are higher when basal levels are optimally suppressed, making detection simpler. Certainly there are advantages of convenience compared to FRTL-5 cells, i.e. the absence of the need for a depletion period. There are, nevertheless, cautions. Not all hTSHRtransfected CHO cells are equally useful; careful selection and evaluation are important. These cells, like FRTL5 cells (34), will age and become less responsive (Tahara, K., and L. D. Kohn, unpublished observations).
FRTL-5 cells with a fresh phenotype have a 90% detection rate; FRTL5 cells with an aged phenotype have a lower stimulating TSHRAb sensitivity and a lower detection limit (-70%). It remains important to consider this in all cell bioassays. There are additional disadvantages, however, in the inability to measure growth IgGs or biofunctions such as iodide uptake.
The present data emphasize the dilemma posed by this disadvantage. In early studies that compared the rat FRTL-5 and primary human thyroid cell assay systems, the observation was made, as in the present study, that about 10% of patients had no stimulating TSHRAbs measurable in either system based on the ability to increase CAMP levels (20). The rat FRTL5 cell system, which could measure growth-stimulating IgGs by their ability to increase thymidine incorporation into DNA, readily detected TSHR autoantibodies in these patients (20, 35) . We now know that one possibility to account for this is the existence of TSHR autoantibodies that perturb the inositol phosphate-arachidonate signal system, as predicted in studies of monoclonal TSHRAb studies (21, 22) . It remains to be seen whether inositol phosphate assays in CHO cells transfected with hTSHR can substitute for the growth assay or whether the activity in both CAMP and arachidonate signal systems in CHO-hTSHR cells will correlate with goiter, as recently indicated in FRTL-5 cells (36, 37).
The early study comparing FRTL5 cells and human primary cultures (20), like the assays herein with CHO-hTSHRtransfected cells, showed that about 20-30% of TSHRAbs measured in the human VS. rat TSHR system were not identical functional populations. Thus, some were better measured in one or the other system. The present study further emphasizes this disparity by showing that stimulating TSHRAbs measured in FRTLS cells and CHO/hTSHR cells appear or tend to correlate with different clinical parameters: goiter and Tc uptake in the case of FRTL5 cell assays, and serum thyroid hormone levels in the CHO-hTSHR assays. This may pose a dilemma in assays of individual patients if further analysis determines that patients with the different types of autoantibodies have different clinical responses or courses. Until such time as this is established, we conclude that both the CHO/hTSHR and FRTL5 rat thyroid system are equally useful in detecting TSHR autoantibodies, with advantages of convenience (CHO system) VS. functional correlations (FRTL-5 cell system) yet to be resolved. We conclude, however, that the CHO-25-hTSHR/chimera system appears to be a useful clinical tool.
Thus, the hTSHR/chimera assay system appears to have predictive value for the success of antithyroid drug therapy in 30% of Graves' patients. If continued follow-up supports long term remission in this group, the assay system will be of major benefit to patients by decreasing morbidity and the costs or consequences of radioiodine therapy and surgery. 
